GERN 250117 1.50C (GERN250117C1500) Stock Options, News & Quotes

US OptionsDetailed Quotes

GERN250117C1500

Watchlist

1.25
-0.27-17.76%

15min DelayClose Jan 17 16:00 ET

1.35High1.25Low

Intraday

5D
Daily

News

Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsJan 15 07:31 ET · Ratings
Geron (GERN) Receives a Buy From Barclays
TipRanksJan 15 07:15 ET · Ratings
Strong Growth and Strategic Financial Management Bolster Buy Rating for Geron's Promising Rytelo Drug
TipRanksJan 15 02:11 ET · Ratings
Stifel Maintains Geron(GERN.US) With Buy Rating
Moomoo NewsJan 13 20:32 ET · Ratings
Geron's Promising Market Growth: Strong Sales Performance and Optimistic Financial Guidance
TipRanksJan 13 20:09 ET
Geron Updates on Q4 Revenue From U.S. Sales of RYTELO
Seeking AlphaJan 13 12:42 ET

Comments

ZenC

Dec 31, 2024 07:28

$Geron (GERN.US)$ Something big is gonna happen

ZenC

Dec 31, 2024 00:52

$Geron (GERN.US)$ Looks like have minimum 50% upside potential

Trytosaveabit

Dec 13, 2024 05:51

Update

$Geron (GERN.US)$ Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...

Trytosaveabit

Dec 10, 2024 08:03

Update

$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis

Tonyco

Nov 17, 2024 17:09

$Geron (GERN.US)$
Almost low enough